Thymosin alpha-1 · research summary

Phenotypic drug discovery: a case for thymosin alpha-1.

Frontiers in medicine · 2024. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Review article discussing phenotypic drug discovery and the pleiotropic mechanisms of thymosin alpha-1
“This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.”

Subjects

Thymosin alpha-1 (Tα1) and its effects on biological systems, immune cells, and disease models
“Thymosin alpha-1 (Tα1, generic drug name: thymalfasin; trade name, Zadaxin) is a 28 amino-acid bioactive peptide originally isolated from the thymus (29–31).”

Reported findings

Thymosin alpha-1 exhibits pleiotropic activity through multiple mechanisms of action, including immunomodulation and metabolic regulation
“Overall, Tα1 exhibits multiple actions across various biological systems and processes, making it a pleiotropic drug having multiple effects or actions on different biological systems.”
Thymosin alpha-1 is considered an example of phenotypic drug discovery because its development was based on observed effects rather than a specific molecular target
“It is clear that Tα1 is a definite example of PDD, because its development was based on observed effects on the immune system rather than a specific, known molecular target.”
Thymosin alpha-1 has been used therapeutically in over 35 countries for conditions including hepatitis B and C, melanoma, and respiratory infections
“Thymalfasin (Zadaxin from SciClone, the only thymosin-based FDA-approved drug) is indeed used in over 35 countries for the treatment of hepatitis B and C, melanoma and a variety of illnesses, including acquired immune deficiency syndrome, respiratory infections, SARS-CoV-2 and sepsis.”

Limitations stated by the authors

Challenges include hit validation, target deconvolution, and safety issues due to the engagement of multiple targets
“Although PDD presents challenges such as hit validation and target deconvolution, significant achievements have been reached in the era of big data.”

Source: PubMed 38903817 · DOI 10.3389/fmed.2024.1388959 · all study summaries

Study type

Review article discussing phenotypic drug discovery and the pleiotropic mechanisms of thymosin alpha-1

“This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.”

Reported findings

Thymosin alpha-1 exhibits pleiotropic activity through multiple mechanisms of action, including immunomodulation and metabolic regulation

“Overall, Tα1 exhibits multiple actions across various biological systems and processes, making it a pleiotropic drug having multiple effects or actions on different biological systems.”

Thymosin alpha-1 is considered an example of phenotypic drug discovery because its development was based on observed effects rather than a specific molecular target

“It is clear that Tα1 is a definite example of PDD, because its development was based on observed effects on the immune system rather than a specific, known molecular target.”

Thymosin alpha-1 has been used therapeutically in over 35 countries for conditions including hepatitis B and C, melanoma, and respiratory infections

“Thymalfasin (Zadaxin from SciClone, the only thymosin-based FDA-approved drug) is indeed used in over 35 countries for the treatment of hepatitis B and C, melanoma and a variety of illnesses, including acquired immune deficiency syndrome, respiratory infections, SARS-CoV-2 and sepsis.”